---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-22-000105"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2022-07-06T23:59:59+00:00"
generated_at: "2026-06-24T20:36:07.703246+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions appoints Sujata Dayal to board; compliance expert joins committees

## Summary
- Sujata Dayal appointed Class II director effective July 15, 2022; term expires at 2023 annual meeting.
- Also appointed to Nominating and Corporate Governance Committee and Special Committee on Manufacturing and Quality Oversight.
- Dayal is VP and Global Chief Compliance Officer at Medline Industries; previously VP healthcare compliance at Johnson & Johnson.
- She will receive an initial equity award of $375,000 in RSUs vesting one-third per year for three years.
- Dayal is an attorney with expertise in healthcare compliance, regulatory law, and anti-corruption.

## SEC filing metadata
- accession: 0001367644-22-000105
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2022-07-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764422000105/0001367644-22-000105-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764422000105/ebs-20220701.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-22-000105
- JSON: https://secwatch.observer/filing/0001367644-22-000105.json
- Plain text: https://secwatch.observer/filing/0001367644-22-000105.txt

## Key facts
- Executive change
  Sujata Dayal was appointed as Class II Director at Emergent BioSolutions Inc..
  - Action: appointed
  - Role: Class II Director
  source text: the Board of Directors (the “Board”) of Emergent BioSolutions Inc. (the “Company”) appointed Sujata Dayal as a Class II director of the Company, effective as of July 15, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1367644/000136764422000105/0001367644-22-000105-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.